Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acrivon Therapeutics, Inc
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
April 24, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
April 16, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
April 10, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces $130 Million Private Placement Financing
April 09, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 28, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
March 05, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
March 04, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
February 08, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
January 03, 2024
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
November 28, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
November 21, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
September 19, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
September 05, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Participate in Two Investor Conferences in September
August 30, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 11, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
July 20, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
June 22, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
May 09, 2023
From
Acrivon Therapeutics, Inc
Via
GlobeNewswire
Tickers
ACRV
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.